Market revenue in 2023 | USD 1,692.5 million |
Market revenue in 2030 | USD 2,644.9 million |
Growth rate | 6.6% (CAGR from 2023 to 2030) |
Largest segment | Glucose testing |
Fastest growing segment | Glucose testing |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Glucose testing, A1C testing, Direct LDL testing, Lipid panel testing, Prostate-specific antigen testing, COVID-19 testing, BUN testing, Vitamin D testing, Thyroid-stimulating hormone testing, Serum Nicotine / Cotinine testing, High sensitivity CRP testing, Testosterone testing, ALT testing, Cortisol testing, Creatinine testing, AST testing, Other blood tests |
Key market players worldwide | Abbott Laboratories, Roche Holding AG ADR, Bio-Rad Laboratories Inc, BioMerieux SA, Quest Diagnostics Inc, Biomerica Inc, Becton Dickinson & Co, Siemens Healthineers AG ADR, Danaher Corp, Trinity Biotech PLC ADR |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to blood testing market will help companies and investors design strategic landscapes.
Glucose testing was the largest segment with a revenue share of 15.21% in 2023. Horizon Databook has segmented the UK blood testing market based on glucose testing, a1c testing, direct ldl testing, lipid panel testing, prostate-specific antigen testing, covid-19 testing, bun testing, vitamin d testing, thyroid-stimulating hormone testing, serum nicotine / cotinine testing, high sensitivity crp testing, testosterone testing, alt testing, cortisol testing, creatinine testing, ast testing, other blood tests covering the revenue growth of each sub-segment from 2018 to 2030.
The UK is expected to exhibit the CAGR of 4.7% over the forecast period owing to new donations, rising prevalence of chronic diseases, and well-established healthcare infrastructure. Data from the Public Health England suggests that an estimated 14,071 individuals, or 6.4% of the population, in the UK were suffering from diabetes in 2017-2018.
Patients suffering from diabetes are at a higher risk of developing cardiovascular complications such as angina, stroke, and heart attack & failure and microvascular complications (amputation and renal disease). Thus, rising incidence of diabetes in the nation is estimated to drive the market growth.
According to NHS, an estimated 85,000 individuals are admitted due to stroke each year. Data from the same source also suggests that over 1 million individuals have survived a stroke in the nation with half of this population suffering from some form of disability causing severe complications.
Horizon Databook provides a detailed overview of country-level data and insights on the UK blood testing market , including forecasts for subscribers. This country databook contains high-level insights into UK blood testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account